Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics to Present at the 8th Annual IPF Summit

Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Aileron Therapeutics to be Included in the Russell Microcap® Index

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Aileron Therapeutics to Present at Two Upcoming Investor Conferences

Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million

Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)